Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)
NCT05263193 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4
Last updated 2022-12-14
Summary
The purpose of this multi-country, retrospective data collection study (chart review) is to describe the effectiveness and safety of caplacizumab in pediatric patients with iTTP.
Conditions
- Immune-mediated Thrombocytopenic Purpura
Interventions
- DRUG
-
Caplacizumab
as in real world practice
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Sciences and Operations · Sanofi
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-08
- Primary Completion
- 2022-10-28
- Completion
- 2022-10-28
- FDA Drug
- Yes
Countries
- France
Study Locations
More Related Trials
-
Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP
NCT04985318 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT00908037 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP
NCT04720261 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT01713738 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety of Oral Thrombopoietin Receptor Agonist in Pediatric Chronic ITP
NCT05846529 ·Status: UNKNOWN
-
Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
NCT02614846 ·Status: UNKNOWN ·Phase: PHASE1
-
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
NCT01713855 ·Status: COMPLETED ·Phase: NA
-
Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
NCT05876221 ·Status: COMPLETED
-
Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura
NCT06291025 ·Status: RECRUITING ·Phase: NA
-
A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
NCT05262881 ·Status: UNKNOWN
-
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT01444417 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
NCT02279173 ·Status: COMPLETED ·Phase: PHASE3
-
Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire
NCT00331357 ·Status: UNKNOWN
-
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
NCT01143038 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
NCT04074187 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
NCT00415532 ·Status: COMPLETED ·Phase: PHASE3
-
Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00116688 ·Status: COMPLETED ·Phase: PHASE3
-
A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
NCT05785468 ·Status: UNKNOWN
-
"Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children"
NCT07014904 ·Status: NOT_YET_RECRUITING
-
Drug Use Investigation for REVOLADE (ITP)
NCT01416311 ·Status: COMPLETED
-
Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
NCT00111475 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura (Kid's ITP Tools)
NCT03123497 ·Status: UNKNOWN
-
Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura
NCT02317133 ·Status: COMPLETED
-
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT00540423 ·Status: COMPLETED ·Phase: PHASE3
-
Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.
NCT04070599 ·Status: COMPLETED ·Phase: PHASE3